Hepatitis B and D

dc.contributor.author	Nabidjonova Durdona Davron qizi
dc.contributor.author	Orinbayeva Zukhra Naurizbaevna
dc.date.accessioned	2026-01-01T21:15:15Z
dc.date.issued	2022-10-29
dc.description.abstract	In recent years, liver diseases have taken an important place among the main causes of premature disability and death of the population. Every year, more than 1 million people of the world are infected with liver diseases. Death due to viral hepatitis is increasing year by year. According to WHO data in 2015, viral hepatitis caused the death of 1.34 million people. 720,000 of them died from chronic liver diseases - liver cirrhosis and cancer, and 470,000 died from hepatocellular carcinoma (WHO, 2015y). In this article, the scientific work conducted on hepatitis B and D diseases on a global scale is studied, and their advantages over each other are explained in more detail
dc.format	application/pdf
dc.identifier.uri	https://geniusjournals.org/index.php/erb/article/view/2451
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/66803
dc.language.iso	eng
dc.publisher	Genius Journals
dc.relation	https://geniusjournals.org/index.php/erb/article/view/2451/2107
dc.source	Eurasian Research Bulletin ; Vol. 13 (2022): ERB; 166-168
dc.source	2795-7675
dc.subject	Hepatitis
dc.subject	Hepatitis D
dc.subject	pathogen
dc.subject	interferon-alpha
dc.title	Hepatitis B and D
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail